CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation, To Acquire 49.9% (CRY)
CryoLife (NYSE: CRY) today announced it has amended its tender offer related to its proposed acquisition of Cardiogenesis Corporation to acquire only 49.9 percent of the outstanding shares of Cardiogenesis.
On April 14, 2011, Cardiogenesis, CryoLife and CryoLife's wholly-owned subsidiary, CL Falcon, Inc., entered into an Amended and Restated Merger Agreement. Pursuant to the Agreement, the tender offer has been revised to provide that CL Falcon, Inc. is offering to acquire only 49.9 percent of the outstanding shares of Cardiogenesis' common stock. If more than 49.9 percent of the outstanding shares are tendered, CL Falcon, Inc. will purchase shares from the tendering shareholders on a prorated basis, as described in tender offer documents filed with the Securities and Exchange Commission. As a result of the Agreement, the Top-Up Option has been removed from the terms of the Offer and will no longer be effective. The tender offer remains scheduled to expire at 12:00 midnight, New York City time, on the evening of May 2, 2011, unless extended.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.